Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524717 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
A Phase 1 study, sponsored by Aragon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02524717 is a Phase 1 study that has completed, run by Aragon Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT02524717, a Phase 1 study, has completed, sponsored by Aragon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.
Interventions
- DRUG JNJ-56021927
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-08-13 |
| Est. Completion | 2017-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02524717
The ClinicalTrials.gov registry entry for NCT02524717 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-56021927 is the first listed.
NCT02524717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02524717 about?
NCT02524717 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function". The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.
What is the current status of trial NCT02524717?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-08-13. Estimated completion is 2017-02-09.
What interventions are being tested in trial NCT02524717?
The interventions under investigation include: JNJ-56021927 (DRUG).
Who is sponsoring clinical trial NCT02524717?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.